Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "pharmacokinetics"

67 News Found

FDA approves Biktarvy label update with data for pregnant adults with HIV
Drug Approval | April 27, 2024

FDA approves Biktarvy label update with data for pregnant adults with HIV

Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV


Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084
Clinical Trials | April 05, 2024

Merck initiates Phase 3 clinical trial of investigational oral KRAS G12C inhibitor MK-1084

For the first-line treatment of certain patients with metastatic non-small cell lung cancer


Merck completes acquisition of Harpoon Therapeutics
News | March 12, 2024

Merck completes acquisition of Harpoon Therapeutics

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager


Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
News | January 26, 2024

Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr

For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)


GSK to acquire Aiolos Bio for US$ 1 billion upfront payment
News | January 10, 2024

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway


Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
Drug Approval | December 18, 2023

Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease

Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation


AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China
News | December 08, 2023

AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China

C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II


Innocan Pharma reports discovery regarding its LPD platform and global CBD research
News | October 25, 2023

Innocan Pharma reports discovery regarding its LPD platform and global CBD research

The company expects that this development could improve the strength of its application to the FDA for new drug approval


Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
Drug Approval | October 23, 2023

Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA

CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases


LG Chem initiates phase 2 clinical trials in patients with defects in MC4R pathway causing obesity and hyperphagia
Clinical Trials | October 23, 2023

LG Chem initiates phase 2 clinical trials in patients with defects in MC4R pathway causing obesity and hyperphagia

LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.